Allergy Therapeutics Share Discussion Threads

[raleigh43] 29/9/2022 19:10

Lots of talk of the US market. What about the EU market?

[raleigh43] 29/9/2022 19:09

Very confident looking.

[macc1] 29/9/2022 09:39

here's an update from the management:

hxxps://youtu.be/0kD8dwzf7GM

[wizzkid211] 29/9/2022 06:12

The third pillar of the strategy, entry into the US market, moves closer, with the upcoming pivotal Phase III Grass MATA MPL trial. The total US allergy immunotherapy market is estimated to be worth $2bn with around 25% of the patients suffering from grass allergy. This indicates potential peak sales for Grass MATA MPL of approximately $300 to $400m per annum.

[wizzkid211] 29/9/2022 06:04

Allergy Therapeutics PLC Unaudited Preliminary Results 2022
29/09/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 29 September 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 0796B

Allergy Therapeutics PLC

29 September 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Unaudited Preliminary Results for the Year ended 30 June 2022

- Phase I VLP Peanut PROTECT trial, incorporating ground-breaking VLP technology, commencing shortly

- Highly successful exploratory field trial for Grass MATA MPL, achieved 40% improvement in combined symptom and medication score compared to placebo, with pivotal Phase III trial on track to start in Q4 2022

- Robust 2022 trading with revenue of GBP72.8m (2021: GBP84.3m) on streamlined portfolio
- Continued growth of key commercial products, Pollinex, Venomil and Acarovac
29 September 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces its unaudited preliminary results for the year ended 30 June 2022.

Highlights (including post-period events)

Financial

- Robust sales of GBP72.8m (2021: GBP84.3m) from commercial portfolio. Strategic streamlining of older products to focus on high value growth products has resulted in a decrease of 14% in actual terms (9%* in constant terms)

- Operating profit pre-R&D of GBP3.4m (2021: GBP16.9m) reflecting portfolio streamlining, COVID-19 headwinds and investment in supply chain

- Strong cash balance of GBP20.5m (2021: GBP40.3m) providing ongoing support for the Group's two key clinical trials

- Full year net loss of GBP13.8m (2021: Net profit of GBP2.9m)
- Announced the fundraise today for GBP7m (before expenses) and loan notes to the value of GBP10m to complete funding of October's Phase I VLP Peanut PROTECT trial, Phase III Grass MATA MPL trial as well as preparations for use of placebo arm of Grass MATA MPL trial to increase safety database and Phase II development of VLP Peanut. Fundraise supported by a number of the Company's largest shareholders.

Operational

- Acceptance by the US FDA of IND application for VLP Peanut with Phase I PROTECT trial in the US due to commence shortly

- Highly successful exploratory field trial for Grass MATA MPL, achieving 40% improvement in combined symptom and medication score compared to placebo

- Continued growth of key commercial products, Pollinex, Venomil and Acarovac, in streamlined portfolio

Manuel Llobet, CEO of Allergy Therapeutics, stated:

"Over the past financial year, we have made significant progress in advancing our clinical pipeline and we are excited to be approaching the start of two key clinical trials in our innovative immunotherapy pipeline. The first-in-human PROTECT trial of our peanut allergy vaccine candidate and the pivotal phase III trial for our grass pollen immunotherapy are significant milestones in our journey to bring these potentially life-changing treatments to patients.

"While market conditions remain challenging for many companies, our leading core European commercial business has been resilient. With a solid cash position and strong, established commercial capabilities that set us apart from solely R&D focused health companies, we are uniquely positioned to create value for our shareholders ."

*Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year-on-year comparison excluding the effects of foreign exchange movements. See table in finance review for an analysis of revenue.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

-S -

Analyst briefing and webcast today

Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a meeting and webcast for analysts and investors at 12pm UK time today. The live webcast can be accessed here . Please contact Consilium Strategic Communications for more details on [e-mail] .

For further information, please contact:

Allergy Therapeutics

[jimmyloser] 28/9/2022 14:47

Jimmyloser steps where angels fear to tread.

How unfortunate to have to release your results into this witches cauldron!

[jimmyloser] 22/9/2022 06:38

..............ahead of its Full Year Results to be announced on

Thursday 29 September 2022.

[raleigh43] 21/9/2022 12:07

Nice spot!

[timbo003] 20/9/2022 10:09

>>>raleigh

AGY will be giving an investor update on 6th October, so I would expect them to release some news either before or on that date.

[raleigh43] 20/9/2022 09:39

Come on AGY, do some investor updates, news, test updates. News!

[raleigh43] 06/9/2022 09:14

After the last one, they announced the CFO was leaving.
They need to big up themselves a bit more IMO.

[jimmyloser] 05/9/2022 11:28

Allergy Therapeutics PLC Allergy Therapeutics at H.C. Wainwright Conference
05/09/2022 7:00am
RNS Non-Regulatory

TIDMAGY

Allergy Therapeutics PLC

05 September 2022

Allergy Therapeutics plc


5 September 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that company management will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference being held September 12-14, 2022, in New York, NY and virtually.

The virtual fireside chat will be available to registered attendees of the conference for on-demand viewing beginning September 12, 2022 at 9:00 a.m. ET/2:00 p.m. BST. A replay of the presentation will be made available under the 'Investors' section on Allergy Therapeutics' website at www.allergytherapeutics.com/investors/results-reports-and-presentations/ .

[jimmyloser] 02/9/2022 14:48

The market seems bouncier today................how about us?

[jimmyloser] 30/8/2022 16:06

me neither jpuff, but I think after they get a result on one of the two blockbusters

[jpuff] 30/8/2022 15:53

Bid for Diurnal today. I wouldn't be surprised to see one here too at these depressed share price levels.

[jimmyloser] 30/8/2022 11:26

Confused



15 July 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergen immunotherapy, today announces its trading update for the year ended 30 June 2022 ahead of its Full Year Results to be announced on Thursday 29 September 2022.

[amishp67] 30/8/2022 11:14

September 23rd Full year results ;)

[raleigh43] 11/8/2022 12:57

Hopefully some trian news coming soon.

[jimmyloser] 25/7/2022 05:20

A most interesting article, courtesy of the BBC

[jimmyloser] 20/7/2022 16:02

lol jpuff, of course they can but more than ever before (impo) they just cannot fail.
But, they will know that more than I do.

[jpuff] 20/7/2022 15:55

Come on you beauty, you can do it!

[jimmyloser] 19/7/2022 15:07

BLUE, that must be the first blue since the cows came home........is that our nadir this time around?

[richsawko] 15/7/2022 07:49

This short term blip happens every year since I have owned these. Must be over 15 years easily and every time there is a good spike it drops back down to lows. I am becoming very despondent about this holding but dare not sell in the HOPE that something will materialise